Takeaway
- Rosuvastatin in patients with HIV at moderate cardiovascular risk did not alter atherosclerosis progression vs placebo at 96 weeks.
- Drug yielded predictable effects on total and low-density lipoprotein cholesterol (LDL-C).
Why this matters
- Risk scores for myocardial infarction lack sensitivity and specificity in people with HIV.
- Benefits of statin therapy in patients with HIV at low-moderate risk may not justify the potential harms.
Key results
- No difference seen between placebo and treatment groups in progression of intima-media thickness from baseline to 96 weeks at any site (all P>.05).
- More adverse events in the treatment group.
- Expected effects seen for total cholesterol and LDL-C: mean change −1.06 mmol/L with drug vs −0.06 mmol/L with placebo; P<.0001.>
Study design
- Randomized, double-blinded, placebo-controlled, multinational trial comparing placebo and rosuvastatin for 96 weeks in people with HIV (stable antiretroviral regimen >3 months; viral load
- Participants were randomly allocated 1:1 (stratified by site) to 20 mg/day rosuvastatin or matched placebo.
- Outcome: atherosclerotic progression (estimated by change in carotid intima-media thickness).
Limitations
- Results were presented without peer review at a conference.
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionalsLogin to
account
Don’t have an account? Get started